U.S. Market Projected to Hit USD 7.06 Billion by 2035 While Europe Market Expected to Reach USD 6.42 Billion as Aging Male Population Fuels Demand for Advanced BPH Therapies.Austin, United States, May ...

Struggling with BPH symptoms? Explore UroLift, a patient-friendly, day-care prostate treatment that avoids major surgery and ...

Data Supported the FDA Approval of the Zenflow Spring® Implant and Delivery System for BPH Additional presented data highlights patient satisfaction & long-term safety SOUTH SAN FRANCISCO, Calif., May ...

Andera Partners said today that it led a $20 million Series D financing round for urology-focused medical device maker ...

Butterfly Medical announced today that it completed its Series C funding round, bringing in $21 million to support its BPH ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...

The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Men pharmacologically treated for benign prostatic hyperplasia (BPH) experienced significant improvements in overactive bladder (OAB) symptoms after treatment with vibegron (Gemtesa), according to ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...